Literature DB >> 12520462

Modulation of cell death in the tumor microenvironment.

Bradly G Wouters1, Marianne Koritzinsky, Roland K Chiu, Jan Theys, Jeroen Buijsen, Philippe Lambin.   

Abstract

The microenvironment of solid human tumors is characterized by heterogeneity in oxygenation. Hypoxia arises early in the process of tumor development because rapidly proliferating tumor cells outgrow the capacity of the host vasculature. Formation of solid tumors thus requires coordination of angiogenesis with continued tumor cell proliferation. However, despite such neovascularization, hypoxia is persistent and frequently found in tumors at the time of diagnosis. Tumors with low oxygenation have a poor prognosis, and strong evidence suggests this is because of the effects of hypoxia on malignant progression, angiogenesis, metastasis, and therapy resistance. The presence of viable hypoxic cells is likely a reflection of the development of hypoxia tolerance resulting from modulation of cell death in the microenvironment. This acquired feature has been explained on the basis of clonal selection-the hypoxic microenvironment selects cells capable of surviving in the absence of normal oxygen availability. However, the persistence and frequency of hypoxia in solid tumors raises a second potential explanation. We suggest that stable microregions of hypoxia may play a positive role in tumor growth. Although hypoxia inhibits cell proliferation and in tumor cells will eventually induce cell death, hypoxia also provides angiogenic and metastatic signals. The development of hypoxia tolerance will thus allow prolonged survival in the absence of oxygen and generation of a persistent angiogenic signal. We will discuss the concept of hypoxia tolerance and review mechanisms used by cancer cells to acquire this phenotype. The concept of hypoxia tolerance has important implications for current and future therapeutic approaches. Most therapeutic efforts to combat hypoxia have focused on targeting the presence of hypoxia itself. Our hypothesis predicts that targeting the biological responses to hypoxia and the pathways leading to hypoxia tolerance may also be attractive therapeutic strategies. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12520462     DOI: 10.1053/srao.2003.50004

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  21 in total

1.  Clostridium to treat cancer: dream or reality?

Authors:  Jan Theys; Philippe Lambin
Journal:  Ann Transl Med       Date:  2015-05

2.  Lysyl oxidase mediates hypoxia-induced radioresistance in non-small cell lung cancer A549 cells.

Authors:  Chongwen Gong; Runxia Gu; Honglin Jin; Yao Sun; Zhenyu Li; Jing Chen; Gang Wu
Journal:  Exp Biol Med (Maywood)       Date:  2015-10-28

3.  Modeling the effect of tumor size in early breast cancer.

Authors:  Claire Verschraegen; Vincent Vinh-Hung; Gábor Cserni; Richard Gordon; Melanie E Royce; Georges Vlastos; Patricia Tai; Guy Storme
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

4.  Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Authors:  Charles Swanton; James M Larkin; Marco Gerlinger; Aron C Eklund; Michael Howell; Gordon Stamp; Julian Downward; Martin Gore; P Andrew Futreal; Bernard Escudier; Fabrice Andre; Laurence Albiges; Benoit Beuselinck; Stephane Oudard; Jens Hoffmann; Balázs Gyorffy; Chris J Torrance; Karen A Boehme; Hansjuergen Volkmer; Luisella Toschi; Barbara Nicke; Marlene Beck; Zoltan Szallasi
Journal:  Genome Med       Date:  2010-08-11       Impact factor: 11.117

5.  Activating transcription factor 4 is translationally regulated by hypoxic stress.

Authors:  Jaime D Blais; Vasilisa Filipenko; Meixia Bi; Heather P Harding; David Ron; Costas Koumenis; Bradly G Wouters; John C Bell
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

6.  [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.

Authors:  Ludwig Dubois; Willy Landuyt; Lieselotte Cloetens; Anne Bol; Guy Bormans; Karin Haustermans; Daniel Labar; Johan Nuyts; Vincent Grégoire; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

7.  Counteraction of pRb-dependent protection after extreme hypoxia by elevated ribonucleotide reductase.

Authors:  P Graff; J Seim; Ø Amellem; H Arakawa; Y Nakamura; K K Andersson; T Stokke; E O Pettersen
Journal:  Cell Prolif       Date:  2004-10       Impact factor: 6.831

8.  Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis.

Authors:  David Hedley; Melania Pintilie; Jennifer Woo; Trudey Nicklee; Andrew Morrison; Diana Birle; Anthony Fyles; Michael Milosevic; Richard Hill
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

9.  Hypoxia and Serum deprivation protected MiaPaCa-2 cells from KAI1-induced proliferation inhibition through autophagy pathway activation in solid tumors.

Authors:  C Y Wu; X Z Guo; H Y Li
Journal:  Clin Transl Oncol       Date:  2014-09-09       Impact factor: 3.405

10.  Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.

Authors:  Violetta Ritter; Franziska Krautter; Diana Klein; Verena Jendrossek; Justine Rudner
Journal:  Cell Death Dis       Date:  2021-07-13       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.